Author

Stephen B. Ruiz

Memorial Sloan Kettering Cancer CenterORCID 0000-0002-1634-9798Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

Daniel A. HelleriD· 2 shared Logan R. HillgeriD· 2 shared Alan M. HanashiD· 1 shared Almudena Chaves PereziD· 1 shared Ana Marie PereaiD· 1 shared Anastasia I. KousaiD· 1 shared Anastasiya Egorova· 1 shared Ashley N. Sullivan· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Daniel A. HellerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

Clemens Hinterleitner, Valentin J.A. Barthet, Hailey V. Goldberg, Kristen C. Vogt, Ana Marie Perea, Logan R. Hillger, Stephen B. Ruiz, Domhnall McHugh, Yu-Jui Ho, Almudena Chaves Perez, Maria Skamagki, Sara Flowers, Hannah C. Styers, Natasha Rekhtman, Xueqian Zhuang, , Scott W. Lowe

P-selectin-targeted fucoidan nanoparticles carrying Navitoclax or dBET6 deplete a senescent-like, lipid-associated macrophage subset, reverse mouse liver and lung fibrosis with less toxicity, and restore checkpoint therapy response in fibrotic tumors.

Science · Sep 24, 2026Peer-reviewedCancer Biology✦ In-depth digest

Galectin-3 is a Nanotherapeutic Target in Graft-versus-Host Disease Mediated Kidney Injury

Magdalini Panagiotakopoulou, Ashley N. Sullivan, Kimon V. Argyropoulos, Anastasia I. Kousa, Logan R. Hillger, Kaitlyn Pierpont, Jorge Nunez, Eric Rosiek, Francesca Mazzoni, Wenfei Kang, Emma Grabarnik, Anastasiya Egorova, Brianna Gipson, Romina Ghale, Stephen B. Ruiz, , Daniel A. Heller

The paper identifies galectin-3 as a target for nanotherapeutic delivery of ruxolitinib to reduce GVHD-related kidney injury and systemic inflammation.

bioRxiv · Nov 19, 2025 · PreprintBioengineering